tralokinumab vs Zumilokibart

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: IL-13 · full Atopic Dermatitis pipeline

tralokinumab · Adbry

Marketed by LEO Pharma and partners

Approved in Atopic Dermatitismonoclonal antibody
Reliable signal

NCT05958407 · Phase 3 · completed

The 235 participants were randomized 2:1 to tralokinumab or placebo and the initial 16-week comparison was double-blinded. The primary clinical endpoint—an Investigator’s Global Assessment score of 0 or 1 at Week 16—was met, occurring in 40.0% of the tralokinumab group versus 10.6% of the placebo group (p<.001).

Next expected readout: June 2030 · NCT07352566 (registry estimate)

Reported efficacy

Percentage of Participants With IGA-AHE Score of 0 (Clear) or 1 (Almost Clear) (At Week 16): Percentage of Participants With IGA-AHE Score of 0 (Clear) or 1 (Almost Clear) (At Week 16): Tralokinumab 40% (95% CI 31.3 to 49.4) vs Placebo 10.6% (95% CI 5 to 20.9) (met)

Result source: NCT05958407

Zumilokibart

Developed by Apogee Therapeutics and partners

Phase 2 in Atopic Dermatitismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: November 2026 · NCT06395948 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointtralokinumabZumilokibart
EASI-7525% vs 12.7%+12.3 vs placebo300 mg Q2W · wk 16 · n 601NCT03131648
8 other results
  • 33.2% vs 11.4% 300 mg Q2W · wk 16 · n 591 · Phase 3 · primary NCT03160885
  • 27.8% vs 6.4% 300 mg Q2W · wk 16 · n 97 · Phase 3 · primary NCT03526861
  • 28.6% vs 6.4% 150 mg Q2W · wk 16 · n 98 · Phase 3 · primary NCT03526861
  • 56% vs 35.7% Q2W+TCS · wk 16 · n 252 · Phase 3 · primary NCT03363854
  • 71.7% vs 56.6% wk 16 · n 53 · Phase 3 · primary NCT04587453
  • 64.2% vs 50.5% wk 16 · n 138 · Phase 3 · primary NCT03761537
  • 68.8% vs 55.3% wk 26 · n 138 · Phase 3 · secondary NCT03761537
  • 49.1% vs 36.1% wk 16 · n 106 · Phase 2 · secondary NCT03562377
—Not reported
IGA 0/1 with 2-point improvement11.6% vs 11.8%−0.2 vs placebowk 12 · n 50NCT02347176
2 other results
  • 19.5% vs 11.8% wk 12 · n 51 · Phase 2 · primary NCT02347176
  • 26.7% vs 11.8% wk 12 · n 52 · Phase 2 · primary NCT02347176
—Not reported
EASI-9014.5% vs 4.1%+10.4 vs placebo300 mg Q2W · wk 16 · n 601NCT03131648
5 other results
  • 18.3% vs 5.5% 300 mg Q2W · wk 16 · n 591 · Phase 3 · secondary NCT03160885
  • 17.5% vs 4.3% 300 mg Q2W · wk 16 · n 97 · Phase 3 · secondary NCT03526861
  • 19.4% vs 4.3% 150 mg Q2W · wk 16 · n 98 · Phase 3 · secondary NCT03526861
  • 32.9% vs 21.4% Q2W+TCS · wk 16 · n 252 · Phase 3 · secondary NCT03363854
  • 45.3% vs 30.2% wk 16 · n 53 · Phase 3 · secondary NCT04587453
—Not reported
EASI, % change-77.8% vs -73.5%−4.3 vs placebowk 16 · n 53NCT04587453—Not reported

EASI-75

tralokinumab
25% vs 12.7%+12.3 vs placebo300 mg Q2W · wk 16 · n 601NCT03131648
8 other results
  • 33.2% vs 11.4% 300 mg Q2W · wk 16 · n 591 · Phase 3 · primary NCT03160885
  • 27.8% vs 6.4% 300 mg Q2W · wk 16 · n 97 · Phase 3 · primary NCT03526861
  • 28.6% vs 6.4% 150 mg Q2W · wk 16 · n 98 · Phase 3 · primary NCT03526861
  • 56% vs 35.7% Q2W+TCS · wk 16 · n 252 · Phase 3 · primary NCT03363854
  • 71.7% vs 56.6% wk 16 · n 53 · Phase 3 · primary NCT04587453
  • 64.2% vs 50.5% wk 16 · n 138 · Phase 3 · primary NCT03761537
  • 68.8% vs 55.3% wk 26 · n 138 · Phase 3 · secondary NCT03761537
  • 49.1% vs 36.1% wk 16 · n 106 · Phase 2 · secondary NCT03562377
Zumilokibart
—Not reported

IGA 0/1 with 2-point improvement

tralokinumab
11.6% vs 11.8%−0.2 vs placebowk 12 · n 50NCT02347176
2 other results
  • 19.5% vs 11.8% wk 12 · n 51 · Phase 2 · primary NCT02347176
  • 26.7% vs 11.8% wk 12 · n 52 · Phase 2 · primary NCT02347176
Zumilokibart
—Not reported

EASI-90

tralokinumab
14.5% vs 4.1%+10.4 vs placebo300 mg Q2W · wk 16 · n 601NCT03131648
5 other results
  • 18.3% vs 5.5% 300 mg Q2W · wk 16 · n 591 · Phase 3 · secondary NCT03160885
  • 17.5% vs 4.3% 300 mg Q2W · wk 16 · n 97 · Phase 3 · secondary NCT03526861
  • 19.4% vs 4.3% 150 mg Q2W · wk 16 · n 98 · Phase 3 · secondary NCT03526861
  • 32.9% vs 21.4% Q2W+TCS · wk 16 · n 252 · Phase 3 · secondary NCT03363854
  • 45.3% vs 30.2% wk 16 · n 53 · Phase 3 · secondary NCT04587453
Zumilokibart
—Not reported

EASI, % change

tralokinumab
-77.8% vs -73.5%−4.3 vs placebowk 16 · n 53NCT04587453
Zumilokibart
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Zumilokibart: no structured comparison results are available for Atopic Dermatitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. tralokinumab: 4 of 4 rows · Zumilokibart: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metrictralokinumab
Dropout rate
4.5%Tralokinumaba
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 43 more results
—Tralokinumab DB
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Tralokinumab OL
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT03131648 · Phase 3
—Q2W
NCT03131648 · Phase 3
—Q4W
NCT03131648 · Phase 3
—Q2W + optional TCS
NCT03131648 · Phase 3 · combination
5.9%300 mg Q2W
NCT03160885 · Phase 3
—Q2W
NCT03160885 · Phase 3
—Q2W
NCT03160885 · Phase 3
—Q4W
NCT03160885 · Phase 3
—Q2W + Optional TCS
NCT03160885 · Phase 3 · combination
—Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q4W+TCS
NCT03363854 · Phase 3 · combination
—Q2W+TCS
NCT03363854 · Phase 3 · combination
7.1%Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q4W+TCS
NCT03363854 · Phase 3 · combination
—300 mg Q4W
NCT03526861 · Phase 3
6.9%300 mg Q2W
NCT03526861 · Phase 3
—300 mg Q2W
NCT03526861 · Phase 3
7%150 mg Q2W
NCT03526861 · Phase 3
—150 mg Q2W
NCT03526861 · Phase 3
—150 mg Q4W
NCT03526861 · Phase 3
—300 mg Q2W
NCT03526861 · Phase 3 · combination
—150 Q2W
NCT03526861 · Phase 3
—300 Q2W
NCT03526861 · Phase 3
—150 Q2W
NCT03526861 · Phase 3
—150 Q4W
NCT03526861 · Phase 3
—300 Q2W
NCT03526861 · Phase 3
—300 Q4W
NCT03526861 · Phase 3
—300 Q2W
NCT03526861 · Phase 3 · combination
31.6%
NCT03587805 · Phase 3 · registry result, not featured evidence
14%Tralokinumab Subcutaneous Dosing b
NCT05194540 · Phase 3 · registry result, not featured evidence
—Tralokinumab+TCS Initial Treatment
NCT05194540 · Phase 3 · registry result, not featured evidence · combination
0%
NCT04587453 · Phase 3 · registry result, not featured evidence · combination
—Safety Follow-up Period: Tralokinu
NCT03761537 · Phase 3 · registry result, not featured evidence · combination
—Treatment Period: Tralokinumab+TCS
NCT03761537 · Phase 3 · registry result, not featured evidence · combination
6.5%
NCT03562377 · Phase 2 · registry result, not featured evidence
20%Tralokinumab Dose 1
NCT02347176 · Phase 2 · registry result, not featured evidence
15.7%Tralokinumab Dose 2
NCT02347176 · Phase 2 · registry result, not featured evidence
7.7%Tralokinumab Dose 3
NCT02347176 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0.6%Tralokinumaba
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 43 more results
—Tralokinumab DB
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Tralokinumab OL
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT03131648 · Phase 3
—Q2W
NCT03131648 · Phase 3
—Q4W
NCT03131648 · Phase 3
—Q2W + optional TCS
NCT03131648 · Phase 3 · combination
—300 mg Q2W
NCT03160885 · Phase 3
—Q2W
NCT03160885 · Phase 3
—Q2W
NCT03160885 · Phase 3
—Q4W
NCT03160885 · Phase 3
—Q2W + Optional TCS
NCT03160885 · Phase 3 · combination
—Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q4W+TCS
NCT03363854 · Phase 3 · combination
—Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q4W+TCS
NCT03363854 · Phase 3 · combination
—300 mg Q4W
NCT03526861 · Phase 3
—300 mg Q2W
NCT03526861 · Phase 3
—300 mg Q2W
NCT03526861 · Phase 3
—150 mg Q2W
NCT03526861 · Phase 3
—150 mg Q2W
NCT03526861 · Phase 3
—150 mg Q4W
NCT03526861 · Phase 3
—300 mg Q2W
NCT03526861 · Phase 3 · combination
—150 Q2W
NCT03526861 · Phase 3
—300 Q2W
NCT03526861 · Phase 3
—150 Q2W
NCT03526861 · Phase 3
—150 Q4W
NCT03526861 · Phase 3
—300 Q2W
NCT03526861 · Phase 3
—300 Q4W
NCT03526861 · Phase 3
—300 Q2W
NCT03526861 · Phase 3 · combination
4.3%
NCT03587805 · Phase 3 · registry result, not featured evidence
—Tralokinumab Subcutaneous Dosing b
NCT05194540 · Phase 3 · registry result, not featured evidence
—Tralokinumab+TCS Initial Treatment
NCT05194540 · Phase 3 · registry result, not featured evidence · combination
—
NCT04587453 · Phase 3 · registry result, not featured evidence · combination
—Safety Follow-up Period: Tralokinu
NCT03761537 · Phase 3 · registry result, not featured evidence · combination
—Treatment Period: Tralokinumab+TCS
NCT03761537 · Phase 3 · registry result, not featured evidence · combination
—
NCT03562377 · Phase 2 · registry result, not featured evidence
—Tralokinumab Dose 1
NCT02347176 · Phase 2 · registry result, not featured evidence
—Tralokinumab Dose 2
NCT02347176 · Phase 2 · registry result, not featured evidence
—Tralokinumab Dose 3
NCT02347176 · Phase 2 · registry result, not featured evidence
Serious AEs
—Tralokinumaba
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 43 more results
1.9%Tralokinumab DB
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.9%Tralokinumab OL
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
3.8%Q2W
NCT03131648 · Phase 3
1.5%Q2W
NCT03131648 · Phase 3
3.9%Q4W
NCT03131648 · Phase 3
4.8%Q2W + optional TCS
NCT03131648 · Phase 3 · combination
—300 mg Q2W
NCT03160885 · Phase 3
1.7%Q2W
NCT03160885 · Phase 3
0%Q2W
NCT03160885 · Phase 3
3.4%Q4W
NCT03160885 · Phase 3
2.9%Q2W + Optional TCS
NCT03160885 · Phase 3 · combination
0%Q2W+TCS
NCT03363854 · Phase 3 · combination
2.1%Q2W+TCS
NCT03363854 · Phase 3 · combination
4.3%Q2W+TCS
NCT03363854 · Phase 3 · combination
0%Q4W+TCS
NCT03363854 · Phase 3 · combination
0.8%Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q4W+TCS
NCT03363854 · Phase 3 · combination
—300 mg Q4W
NCT03526861 · Phase 3
—300 mg Q2W
NCT03526861 · Phase 3
—300 mg Q2W
NCT03526861 · Phase 3
—150 mg Q2W
NCT03526861 · Phase 3
—150 mg Q2W
NCT03526861 · Phase 3
—150 mg Q4W
NCT03526861 · Phase 3
—300 mg Q2W
NCT03526861 · Phase 3 · combination
3.1%150 Q2W
NCT03526861 · Phase 3
1%300 Q2W
NCT03526861 · Phase 3
0%150 Q2W
NCT03526861 · Phase 3
0%150 Q4W
NCT03526861 · Phase 3
0%300 Q2W
NCT03526861 · Phase 3
0%300 Q4W
NCT03526861 · Phase 3
3%300 Q2W
NCT03526861 · Phase 3 · combination
9%
NCT03587805 · Phase 3 · registry result, not featured evidence
—Tralokinumab Subcutaneous Dosing b
NCT05194540 · Phase 3 · registry result, not featured evidence
0%Tralokinumab+TCS Initial Treatment
NCT05194540 · Phase 3 · registry result, not featured evidence · combination
—
NCT04587453 · Phase 3 · registry result, not featured evidence · combination
0%Safety Follow-up Period: Tralokinu
NCT03761537 · Phase 3 · registry result, not featured evidence · combination
0.7%Treatment Period: Tralokinumab+TCS
NCT03761537 · Phase 3 · registry result, not featured evidence · combination
2.8%
NCT03562377 · Phase 2 · registry result, not featured evidence
6%Tralokinumab Dose 1
NCT02347176 · Phase 2 · registry result, not featured evidence
3.9%Tralokinumab Dose 2
NCT02347176 · Phase 2 · registry result, not featured evidence
0%Tralokinumab Dose 3
NCT02347176 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
nasopharyngitis 16.7% (placebo 7.6%)
injection site reaction 6.4% (placebo 1.3%)
dermatitis atopic 5.8% (placebo 5.1%)
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 29 more results
injection site reaction 7.9% (placebo 1.3%)
nasopharyngitis 7.5% (placebo 7.6%)
covid-19 0% (placebo 0%)
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Q2W
dermatitis atopic 25.2% (placebo 38.3%)
viral upper respiratory tract infection 23.1% (placebo 20.9%)
conjunctivitis 7.1% (placebo 2%)
NCT03131648 · Phase 3
Q2W
viral upper respiratory tract infection 20.6% (placebo 20.9%)
dermatitis atopic 16.2% (placebo 38.3%)
headache 8.8% (placebo 5.1%)
NCT03131648 · Phase 3
Q4W
viral upper respiratory tract infection 23.7% (placebo 20.9%)
dermatitis atopic 18.4% (placebo 38.3%)
bronchitis 9.2% (placebo 2%)
NCT03131648 · Phase 3
Q2W + optional TCS
viral upper respiratory tract infection 25.4% (placebo 20.9%)
dermatitis atopic 21.8% (placebo 38.3%)
conjunctivitis 7.3% (placebo 2%)
NCT03131648 · Phase 3 · combination
Q2W
dermatitis atopic 16.4% (placebo 33.5%)
upper respiratory tract infection 10% (placebo 8.5%)
viral upper respiratory tract infection 8.3% (placebo 8.5%)
NCT03160885 · Phase 3
Q2W
upper respiratory tract infection 15.4% (placebo 8.5%)
dermatitis atopic 14.3% (placebo 33.5%)
viral upper respiratory tract infection 9.9% (placebo 8.5%)
NCT03160885 · Phase 3
Q4W
dermatitis atopic 15.7% (placebo 33.5%)
upper respiratory tract infection 10.1% (placebo 8.5%)
viral upper respiratory tract infection 6.7% (placebo 8.5%)
NCT03160885 · Phase 3
Q2W + Optional TCS
dermatitis atopic 20.4% (placebo 33.5%)
upper respiratory tract infection 11.6% (placebo 8.5%)
viral upper respiratory tract infection 10.4% (placebo 8.5%)
NCT03160885 · Phase 3 · combination
Q2W+TCS
viral upper respiratory tract infection 19% (placebo 17.1%)
dermatitis atopic 7.6% (placebo 4.9%)
conjunctivitis 3.8% (placebo 2.4%)
NCT03363854 · Phase 3 · combination
Q2W+TCS
viral upper respiratory tract infection 21.1% (placebo 17.1%)
dermatitis atopic 8.4% (placebo 4.9%)
headache 7.4% (placebo 2.4%)
NCT03363854 · Phase 3 · combination
Q2W+TCS
viral upper respiratory tract infection 17.4% (placebo 17.1%)
upper respiratory tract infection 10.1% (placebo 4.9%)
injection site reaction 7.2% (placebo 0%)
NCT03363854 · Phase 3 · combination
Q4W+TCS
viral upper respiratory tract infection 13% (placebo 17.1%)
headache 7.2% (placebo 2.4%)
injection site reaction 5.8% (placebo 0%)
NCT03363854 · Phase 3 · combination
Q2W+TCS
viral upper respiratory tract infection 19.4% (placebo 17.1%)
conjunctivitis 11.1% (placebo 2.4%)
headache 8.7% (placebo 2.4%)
NCT03363854 · Phase 3 · combination
150 Q2W
viral upper respiratory tract infection 19.4% (placebo 8.5%)
dermatitis atopic 12.2% (placebo 11.7%)
upper respiratory tract infection 8.2% (placebo 4.3%)
NCT03526861 · Phase 3
300 Q2W
viral upper respiratory tract infection 12.4% (placebo 8.5%)
upper respiratory tract infection 11.3% (placebo 4.3%)
dermatitis atopic 7.2% (placebo 11.7%)
NCT03526861 · Phase 3
150 Q2W
pharyngitis 25% (placebo 4.3%)
acne 8.3% (placebo 4.3%)
acute sinusitis 8.3% (placebo 1.1%)
NCT03526861 · Phase 3
150 Q4W
dermatitis atopic 14.3% (placebo 11.7%)
acne 7.1% (placebo 4.3%)
attention deficit/hyperactivity disorder 7.1% (placebo 0%)
NCT03526861 · Phase 3
300 Q2W
influenza 18.2% (placebo 1.1%)
upper respiratory tract infection 18.2% (placebo 4.3%)
viral upper respiratory tract infection 18.2% (placebo 8.5%)
NCT03526861 · Phase 3
300 Q4W
bacterial vaginosis 7.7% (placebo 0%)
conjunctivitis 7.7% (placebo 0%)
inappropriate schedule of drug administration 7.7% (placebo 0%)
NCT03526861 · Phase 3
300 Q2W
viral upper respiratory tract infection 18.8% (placebo 8.5%)
upper respiratory tract infection 10.7% (placebo 4.3%)
dermatitis atopic 8.1% (placebo 11.7%)
NCT03526861 · Phase 3 · combination
nasopharyngitis 22.2%
atopic dermatitis 21%
covid-19 17.6%
NCT03587805 · Phase 3 · registry result, not featured evidence
injection site reaction 5.9%
dermatitis atopic 4.4%
conjunctivitis 2.9%
NCT05194540 · Phase 3 · registry result, not featured evidence · combination
viral upper respiratory tract infection 2.7% (placebo 1.2%)
arthralgia 1.3% (placebo 0%)
cholelithiasis 1.3% (placebo 0%)
NCT03761537 · Phase 3 · registry result, not featured evidence · combination
viral upper respiratory tract infection 26.8% (placebo 1.2%)
headache 15.2% (placebo 0%)
upper respiratory tract infection 7.2% (placebo 0%)
NCT03761537 · Phase 3 · registry result, not featured evidence · combination
dermatitis atopic 11.2% (placebo 12.1%)
viral upper respiratory tract infection 9.3% (placebo 2.8%)
headache 2.8% (placebo 1.9%)
NCT03562377 · Phase 2 · registry result, not featured evidence
nasopharyngitis 22% (placebo 11.8%)
upper respiratory tract infection 10% (placebo 9.8%)
dermatitis atopic 6% (placebo 7.8%)
NCT02347176 · Phase 2 · registry result, not featured evidence
nasopharyngitis 15.7% (placebo 11.8%)
upper respiratory tract infection 11.8% (placebo 9.8%)
headache 7.8% (placebo 3.9%)
NCT02347176 · Phase 2 · registry result, not featured evidence
nasopharyngitis 25% (placebo 11.8%)
headache 7.7% (placebo 3.9%)
upper respiratory tract infection 7.7% (placebo 9.8%)
NCT02347176 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 41 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

tralokinumab

IGA-AHE 0 1 40% (n=156) vs 10.6% (n=79) placebo @ 16wk
responder rate · % of participants
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
IGA-AHE Improvement 2 40.1% (n=156) vs 10.6% (n=79) placebo @ 16wk
absolute value · percentage points
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
HECSI-75 64.1% (n=156) vs 33.8% (n=79) placebo @ 16wk
responder rate · % of participants
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
HECSI-50 79.7% (n=156) vs 50.7% (n=79) placebo @ 16wk
responder rate · % of participants
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
HECSI-90 41.7% (n=156) vs 10.9% (n=79) placebo @ 16wk
responder rate · % of participants
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
HECSI -69.9% (n=156) vs -31.4% (n=79) placebo @ 16wk
percent change · % of baseline
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
HESD Itch Improvement 4 47.3% (n=153) vs 20.7% (n=78) placebo @ 16wk
absolute value · percentage points
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
HESD Itch -51.1% (n=155) vs -23.7% (n=78) placebo @ 16wk
percent change · % of baseline
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
HESD Pain Improvement 4 45.3% (n=138) vs 13.3% (n=73) placebo @ 16wk
absolute value · percentage points
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
HESD Pain -60.1% (n=153) vs -13.2% (n=78) placebo @ 16wk
percent change · % of baseline
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
HEIS -64.9% (n=154) vs -28.5% (n=77) placebo @ 16wk
percent change · % of baseline
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
DLQI -60.9% (n=154) vs -21% (n=77) placebo @ 16wk
percent change · % of baseline
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3

+ 46 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: tralokinumab's landscape · Zumilokibart's landscape